Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C2 | P08235 | 5/20 | 0.42 |
| ▸ | MMP12 | P39900 | 1/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.38 |
| ▸ | AURKA | O14965 | 1/20 | 0.38 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.38 |
| ▸ | JAK2 | O60674 | 1/20 | 0.38 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.38 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.38 |
| ▸ | PAK4 | O96013 | 1/20 | 0.38 |
| ▸ | ABL1 | P00519 | 1/20 | 0.38 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.38 |
| ▸ | FYN | P06241 | 1/20 | 0.38 |
| ▸ | RET | P07949 | 1/20 | 0.38 |
| ▸ | MET | P08581 | 1/20 | 0.38 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.38 |
| ▸ | PIM1 | P11309 | 1/20 | 0.38 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.38 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.38 |
| ▸ | FLT1 | P17948 | 1/20 | 0.38 |
| ▸ | LTK | P29376 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1190598 | 0.80 | MMP12 (0.53) | NR3C2MMP12CYP11B1CYP11B2MGLL | |
| SCHEMBL5800054 | 0.80 | NR3C2 (0.42) | NR3C2MMP12CYP11B1CYP11B2MGLL | |
| SCHEMBL1191558 | 0.80 | NR3C2 (0.43) | NR3C2MMP12CYP11B1CYP11B2AKR1B1 | |
| SCHEMBL2796664 | 0.78 | NR3C2 (0.41) | NR3C2MMP12CYP11B1CYP11B2MGLL | |
| SCHEMBL4293316 | 0.78 | NR3C2 (0.41) | NR3C2MMP12CYP11B1CYP11B2MGLL | |
| SCHEMBL1190524 | 0.78 | KIF11 (0.43) | NR3C2MMP12METCYP11B1CYP11B2 | |
| SCHEMBL10285580 | 0.76 | PARP1 (0.56) | NR3C2MMP12CYP11B1CYP11B2MGLL | |
| SCHEMBL2002517 | 0.76 | MGLL (0.45) | NR3C2MGLLALDH1A1KMT2A | |
| SCHEMBL18352011 | 0.76 | NR3C2 (0.42) | NR3C2MMP12CYP11B1CYP11B2MGLL | |
| SCHEMBL21384876 | 0.76 | NR3C2 (0.40) | NR3C2MMP12CYP11B1CYP11B2MGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 120 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12583866-B2 | Pyrido[2,3-b][1,4]oxazines or tetrahydropyrido[2,3-b][1,4]oxazepines as IAP antagonists | BEONE MEDICINES I GMBH (CH) | 2026-03-24 | — | — | US | disclosed |
| US-20250388583-A1 | COMPOUNDS AND METHOD FOR PKMYT1 INHIBITION | ENGINE BIOSCIENCES PTE LTD (SG) | 2025-12-25 | — | — | US | disclosed |
| US-12421226-B2 | Heteroaryl compounds as necrosis inhibitors, composition and method using the same | ACCRO BIOSCIENCE (HK) LIMITED (HK) | 2025-09-23 | — | — | US | disclosed |
| US-12338255-B2 | Bicyclic substituted sulfonylurea compounds as inhibitors of interleukin-1 activity | VIVA STAR BIOSCIENCES (SUZHOU) CO., LTD. (CN) | 2025-06-24 | — | — | US | disclosed |
| EP-4543881-A1 | COMPOUNDS AND METHOD FOR PKMYT1 INHIBITION | Engine Biosciences Pte. Ltd. (SG) | 2025-04-30 | — | — | EP | disclosed |
| US-20250034134-A1 | 15-PGDH INHIBITOR AND USE THEREOF | Wuhan Humanwell Innovative Drug Research and Development Center Limited Company (CN) | 2025-01-30 | — | — | US | disclosed |
| EP-4482842-A1 | NOVEL BICYCLIC SUBSTITUTED SULFONYLUREA COMPOUNDS AS INHIBITORS OF INTERLEUKIN- 1 ACTIVITY | Viva Star Biosciences (Suzhou) Co., Ltd. (CN) | 2025-01-01 | — | — | EP | disclosed |
| CN-119110803-A | Novel bicyclic substituted sulfonylurea compounds as inhibitors of interleukin-1 activity | 唯久生物技术(苏州)有限公司 | 2024-12-10 | — | — | CN | disclosed |
| EP-4434986-A1 | 15-PGDH INHIBITOR AND USE THEREOF | Wuhan Humanwell Innovative Drug Research and Development Center Limited Company (CN) | 2024-09-25 | — | — | EP | disclosed |
| CN-118480049-A | PKMYT1 inhibitor and preparation method and application thereof | 南京同诺康医药科技有限公司 | 2024-08-13 | — | — | CN | disclosed |
| WO-2007077961-A2 | FUSED HETEROCYCLIC COMPOUNDS AND THEIR USE AS MINERALOCORTICOID RECEPTOR LIGANDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-07-12 | — | — | WO | disclosed |
| US-7205295-B2 | Benzoxazin-3-ones and derivatives thereof as therapeutic agents | WARNER-LAMBERT COMPANY LLC (US) | 2007-04-17 | — | — | US | disclosed |
| EP-1569653-A1 | BENZOXAZIN-3-ONES AND DERIVATIVES THEREOF AS INHIBITORS OF PI3K | Warner-Lambert Company LLC (US) | 2005-09-07 | — | — | EP | disclosed |
| EP-1040111-B1 | INTEGRIN RECEPTOR ANTAGONISTS | MERCK & CO INC (US) | 2005-06-22 | — | — | EP | disclosed |
| WO-2004052373-A1 | BENZOXAZIN-3-ONES AND DERIVATIVES THEREOF AS INHIBITORS OF PI3K | WARNER-LAMBERT COMPANY LLC (US) | 2004-06-24 | — | — | WO | disclosed |
| US-20040121996-A1 | Benzoxazin-3-ones and derivatives thereof as therapeutic agents | BARVIAN NICOLE (US) | 2004-06-24 | — | — | US | disclosed |
| US-6268378-B1 | TREATING AND PREVENTING OSTEOPOROSIS, AND INHIBITING VASCULAR RESTENOSIS, DIABETIC RETINOPATHY, MACULAR DEGENERATION, ANGIOGENESIS, ATHEROSCLEROSIS, INFLAMMATION, VIRAL DISEASE, AND TUMOR GROWTH. | MERCK & CO., INC. | 2001-07-31 | — | — | US | disclosed |
| CN-1284955-A | Integrin receptor antagonists | MERCK & CO INC (US) | 2001-02-21 | — | — | CN | disclosed |
| US-6066648-A | USEFUL IN INHIBITING BONE RESORPTION, TREATING AND PREVENTING OSTEOPOROSIS, AND INHIBITING VASCULAR RESTENOSIS, DIABETIC RETINOPATHY, MACULAR DEGENERATION, ANGIOGENESIS, ATHEROSCLEROSIS, INFLAMMATION, VIRAL DISEASE, AND TUMOR GROWTH | MERCK & CO., INC. (US) | 2000-05-23 | — | — | US | disclosed |
| US-6017926-A | Integrin receptor antagonists | MERCK & CO., INC. (US) | 2000-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12421226-B2 | Heteroaryl compounds as necrosis inhibitors, composition and method using the same | TNF, LITAF, PNLIP | NR3C2 1462/4885MMP12 644/4885DYRK1A 4546/4885 |
| US-20040121996-A1 | Benzoxazin-3-ones and derivatives thereof as therapeutic agents | XDH, HAX1, CYP4X1 | NR3C2 1315/4885MMP12 608/4885DYRK1A 167/4885 |
| US-12583866-B2 | Pyrido[2,3-b][1,4]oxazines or tetrahydropyrido[2,3-b][1,4]oxazepines as IAP antagonists | BIRC2, BIRC3, BIRC5 | NR3C2 4225/4885MMP12 967/4885DYRK1A 1443/4885 |
| US-20250034134-A1 | 15-PGDH INHIBITOR AND USE THEREOF | HPGD, UGDH, PGD | NR3C2 963/4885MMP12 828/4885DYRK1A 4357/4885 |
| US-12338255-B2 | Bicyclic substituted sulfonylurea compounds as inhibitors of interleukin-1 activity | IL1B, IL1A, IL18 | NR3C2 4324/4885MMP12 1808/4885DYRK1A 4302/4885 |
| US-20250388583-A1 | COMPOUNDS AND METHOD FOR PKMYT1 INHIBITION | PKMYT1, PKN1, PRKCB | NR3C2 1291/4885MMP12 4611/4885DYRK1A 1631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.